pharmafile | November 28, 2022 | Appointment | Business Services |
Following a positive NICE recommendation for VAZKEPA® (icosapent ethyl), which has allowed Amarin to continue with its commercial expansion, Amarin has appointed Scott Curley as general manager of its UK and Ireland team.
Scott previously worked at AstraZeneca, where he held many roles including some in leadership positions such as general manager of Hong Kong and Macau, member of the board of directors for the Hong Kong Association of the Pharmaceutical Industry, head of global and US commercial excellence, global head of commercial operations for the respiratory franchise, and global medicines lead for integrated patient solution. He also previously worked at GlaxoSmithKline and SmithKlineBeecham, and brings with him a vast sum of knowledge and experience.
In his new role, Scott plans to focus on developing and growing Amarin’s organisational infrastructure, ensuring the successful launch of new products, including VASKEPA.
Commenting on his new role, Scott said, “I’m really excited to join Amarin, it’s a company that immediately feels different to traditional Big Pharma. My new role offers a unique opportunity to build a new UK and Ireland affiliate from the ground up. It’s also rare to come to market in the CVD space immediately backed by a landmark study with NICE approval. With this, we have the potential to have a positive and lasting impact on thousands of UK and Irish patients.”
He continued: “Doing all we can for patients with CVD will be our moral compass and the driving force behind our future success. For me, Amarin’s CVD mission is personal as well as professional. Having lost three of my grandparents to CVD and having experienced first-hand the devastating impact it had on them and my family, I am determined to improve the lives of as many CVD patients across the UK and Ireland as we can.”